Get the Stockscreener App
1.52
3.80%
-0.06
Inhibikase Therapeutics Inc stock is traded at $1.52, with a volume of 83,516.
It is down -3.80% in the last 24 hours and down -22.05% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$1.58
Open:
$1.56
24h Volume:
83,516
Relative Volume:
0.35
Market Cap:
$113.00M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.4856
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
-14.12%
1M Performance:
-22.05%
6M Performance:
-33.04%
1Y Performance:
+10.95%
1-Day Range:
$1.46
$1.56
1-Week Range:
$1.46
$1.8332
52-Week Range:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
678-392-3419
Address
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Compare IKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.52 | 117.46M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Inhibikase Therapeutics (NYSE:IKT) and Genocea Biosciences (NASDAQ:GNCAQ) Head to Head Comparison - Defense World
Published on: 2025-08-01 22:50:53 - Newser
Intraday pattern recognizer results for Inhibikase Therapeutics Inc.ROI Focused Watchlist with Trade Confidence - Newser
Visual analytics tools that track Inhibikase Therapeutics Inc. performanceTen-Year Sector Performance and Summary Analysis - Newser
How high can Inhibikase Therapeutics Inc. stock goIntraday Movement Recap and Chart Summary - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockBear Market Safe Zone Technical Analysis - Newser
When is Inhibikase Therapeutics Inc. stock expected to show significant growthReal Time Outlook With High Returns - jammulinksnews.com
What are the latest earnings results for Inhibikase Therapeutics Inc.Breakout Stocks Opportunities Backed By Experts - jammulinksnews.com
Risk vs reward if holding onto Inhibikase Therapeutics Inc.Dividend Strategy Summary With 10-Year Outlook - Newser
What indicators show strength in Inhibikase Therapeutics Inc.Volume Spike Detection for Early Breakouts - Newser
Hedge funds investors in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) see US$17m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Strategies to average down on Inhibikase Therapeutics Inc.Support and Resistance Zone Summary Chart - Newser
Candlestick signals on Inhibikase Therapeutics Inc. stock todayFree Secure Capital Picks With Upside Potential - Newser
Real Time Chart Alerts Flash Bullish on Inhibikase Therapeutics Inc.Beginner Friendly Stock Selection Guide Updated - metal.it
Inhibikase Therapeutics Inc. Nearing Breakout Level After BounceWeekly Chart Analysis With Entry Advice Provided - metal.it
What makes Inhibikase Therapeutics Inc. stock price move sharplyFree ROI Driven Equity Selection With Safety - Newser
Real time pattern detection on Inhibikase Therapeutics Inc. stockVolume Based Swing Signal Prediction Map - Newser
Does Inhibikase Therapeutics Inc. stock perform well during market downturnsStock Market Data Feed For Consistent Profits - jammulinksnews.com
Is it the right time to buy Inhibikase Therapeutics Inc. stockLow Risk Forecasts For Smart Trading - jammulinksnews.com
Inhibikase Therapeutics Inc. Inches Above Key Support — Safe to HoldFundamental Growth Stock Analysis Shows Strength - metal.it
How does Inhibikase Therapeutics Inc. compare to its industry peersInvest confidently with data-driven strategies - jammulinksnews.com
How strong is Inhibikase Therapeutics Inc. company’s balance sheetFree Stock Market Forecast Reports - jammulinksnews.com
Candlestick signals on Inhibikase Therapeutics Inc. stock today AI-Powered Stock Trend Movement Analysis - Newser
What catalysts could drive Inhibikase Therapeutics Inc. stock higher in 2025Market-beating performance - jammulinksnews.com
Risk vs reward if holding onto Inhibikase Therapeutics Inc. Daily Market Entry Strategy with Tools - Newser
Is Inhibikase Therapeutics Inc. stock overvalued or undervaluedDiscover hidden gems in the stock market - jammulinksnews.com
How Inhibikase Therapeutics Inc. stock performs during market volatilityDeep Learning Stock Forecast for Investors - Newser
What is the risk reward ratio of investing in Inhibikase Therapeutics Inc. stockUnlock expert market analysis instantly - jammulinksnews.com
how inhibikase therapeutics inc. stock performs during market volatilityFree Long-Term Wealth Growth Plan - Newser
New Product Launches: Will They Boost Inhibikase Therapeutics Inc. Stock in 2025Free Access to Community with 300% Return - Newser
What analysts say about Inhibikase Therapeutics Inc. stockPowerful growth strategies - PrintWeekIndia
Inhibikase Therapeutics Inc. Stock Analysis and ForecastHigh-yield trading alerts - Autocar Professional
What drives Inhibikase Therapeutics Inc. stock priceConsistently high yield - Autocar Professional
How high can Inhibikase Therapeutics Inc. stock price go in 2025Rapid profit acceleration - jammulinksnews.com
Is Inhibikase Therapeutics Inc. a good long term investmentPhenomenal investment performance - Autocar Professional
What analysts say about Tianci International Inc. stockTriple-digit profit margins - jammulinksnews.com
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inhibikase Therapeutics Inc Stock (IKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):